RxDoctor Payments Data

Fernando Lapetina Irizarry, MD

Cardiovascular Disease · Santurce, PRNPI 1154490449

Payments from drug & device makers

$3,512in general payments, 2019–2025

Across 65 payments — averaging $54.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • Abbott$539
  • Edwards Lifesciences$385
  • Boston Scientific$379
  • Johnson & Johnson$253
  • AstraZeneca$112
  • plus $344 from 8 others

What the payments were for

  • Consulting fees$1,50043%
  • Food & beverage$1,93755%
  • Gifts$752%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$1,500
Abbott13$539
Edwards Lifesciences17$385
Boston Scientific14$379
Johnson & Johnson6$253
AstraZeneca1$112
Chiesi USA, Inc.3$108
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$71
Medtronic(2 entities)4$65
PBG Puerto Rico LLC1$25
E.r. Squibb & Sons, L.L.C.1$22
Novartis1$22
Terumo Medical Corporation1$20
Cardinal Health P.r. 120 Inc1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,512 in reported general payments places this provider in the 50th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$18,994
Medicare patients
55
Services billed
158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$10,219
XareltoRivaroxaban12$6,842
Metoprolol Succinate59$621
Hydrochlorothiazide75$438
Amlodipine Besylate84$372
Losartan Potassium47$325
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide34$324
Enalapril Maleate13$284
Digoxin12$241
Irbesartan13$168
Rosuvastatin Calcium14$153
Furosemide24$132
Lisinopril28$123
Carvedilol18$98
ClopidogrelClopidogrel Bisulfate12$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$253$6,84212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in Santurce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →